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THE EFFECTS OF BMP9 AND PERINATAL CHOLINE SUPPLEMENTATION 
ON THE APP.PS1 MOUSE MODEL OF ALZHEIMER’S DISEASE 
 
ELLEN M. BRUNS 
ABSTRACT 
 Alzheimer’s disease (AD), a highly prevalent neurodegenerative illness, 
represents a major challenge to biomedical science due to the current lack of effective 
therapies. Preventative strategies are often overlooked although they have the potential to 
be highly beneficial. Nutrition is a critical aspect of health and prenatal nutrition has the 
potential to impact one’s health throughout life. Choline is an essential nutrient that 
although present in many foods, is often under-consumed in the United States. Several 
studies find that only 15% of pregnant mothers meet the adequate daily intake of choline. 
Prenatal choline has been associated with enhanced cognitive performance of offspring in 
both rodents and humans. Previous studies have shown that high perinatal intake of 
choline ameliorates AD-related pathology features in the APP.PS1 mouse model of this 
disease. In this study, perinatal diets containing supplemental and standard levels of 
choline were given to APP.PS1 and WT mice. Additionally, to investigate the effects of 
bone morphogenic protein 9, (BMP9) mice either had two (Bmp9+/+) or no copies of the 
gene (Bmp9-/-). BMP9 is a secreted protein that facilitates the acquisition of the 
cholinergic phenotype of basal forebrain cholinergic neurons (BFCNs). BFCNs are 
particularly vulnerable to the pathophysiologic process of AD. Because of this, BMP9 
may represent a mechanism by which perinatal choline supplementation acts to 
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ameliorate pathologic features of AD. Behavioral tests were conducted to evaluate motor 
activity, anxiety, and cognition longitudinally at 6 and 9 months of age. APP.PS1 mice 
given control-diet displayed significantly lower anxiety-like behaviors and greater 
locomotor activity than their counterparts given choline supplementation during 
development. Additionally, mice with Bmp9 gene inactivations exhibited fewer anxiety-
like behaviors and greater locomotor activity than Bmp9+/+ mice. In the Barnes maze 
test of visuo-spatial learning and memory, APP.PS1 mice were more impaired as 
compared to WT mice, and this impairment was reduced in APP.PS1/Bmp9+/+ mice that 
had received perinatal choline supplementation. Bmp9-/- mice also exhibited impairments 
in escape behavior in the Barnes maze and this behavior was largely unaffected by 
perinatal choline. Coronal brain sections were stained with a β-amyloid antibody and 
hippocampal and cortical regions were analyzed for amyloid plaque content. Amyloid 
plaque counts increased with perinatal choline supplementation in the hippocampus, in 
contrast with previous works. Additionally, males with Bmp9 gene inactivations had 
lower plaque levels in the hippocampus than the Bmp9-/- males. These data do not 
directly align with behavioral data or previous reports that perinatal choline 
supplementation ameliorates amyloidosis in AD mouse models. Despite the contradictory 
amyloid plaque data, perinatal choline supplementation ameliorates spatial learning and 
memory impairment in APP.PS1 mice in this study. This is consistent with previous 
reports and supports previous literature indicating the life-long beneficial effects of 
supplemental choline during development on cognitive function. In the context of AD, 
dietary factors that affect cognitive function could represent a valuable preventative 
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strategy. This study provides insight into the effects of Bmp9 gene inactivations in the 
context of AD and perinatal diet containing supplemental choline.  
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INTRODUCTION 
 
 Alzheimer’s disease (AD), a neurodegenerative disease of the central nervous 
system is the most common cause of dementia. It is a devastating illness characterized by 
progressive cognitive decline, loss of memory, and behavioral disorders which severely 
impact quality of life. Unfortunately, it is a highly prevalent disease currently lacking in 
effective therapies and therefore represents a major challenge to biomedical science. AD 
research has had little focus on preventative strategies, although the prevention of 
cognitive impairment or delay of cognitive decline are highly desirable goals.  
Nutrition and prenatal nutrition in particular, are crucial contributors to health and 
wellbeing that have lifelong impacts. Choline is an essential nutrient which must be 
obtained from the diet (Institute of Medicine 1998). Although it is present in many foods, 
many studies show that consumption of choline in the United States is inadequate 
(Wallace 2016). Insufficient choline intake is associated with various pathological effects 
such as liver dysfunction (Zeisel 1991), muscle damage (da Costa 2004), death of 
lymphocytes (da Costa 2006) and deficient maternal choline consumption can increase 
the risk of neural tube defects (Shaw 2004, Shaw 2009). Recommended daily amounts of 
choline are increased during pregnancy (Institute of Medicine 1998), but the National 
Health and Nutrition Examination Study found that only 15% of pregnant women meet 
the recommended levels of choline consumption. (Jensen 2007) Several studies link 
prenatal maternal choline consumption to the cognitive ability of offspring in both 
humans and rodents. In behavioral tests, rats prenatally supplemented with choline 
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exhibit enhanced spatial memory (Meck 1988, Schenk 1995, Mellott 2004) and temporal 
processing (Meck 1997, Buhusi 2008, Cheng 2008) as compared to control diet 
counterparts. As in these rodent examples, human maternal consumption of choline has 
been shown to be influential on children’s cognitive performance. The Viva Project in 
Massachusetts surveyed diets of pregnant women and found children of mothers who met 
the adequate intake (AI) of choline during pregnancy to have better memory function at 7 
years of age as compared to children of mothers who consumed only 50% of the AI of 
choline (Boeke 2013). These memory-enhancing effects of prenatal nutrition have also 
been shown to continue throughout life. In aged rats, a high choline prenatal diet 
prevented the age-related memory decline observed in non-supplemented rats (Meck 
2007). 
In addition to preventing age-related impairments, perinatal choline has also been 
shown to decrease various pathogenic effects of AD in an AD mouse model (Mellott 
2017, Velazquez 2019). Pathogenesis of AD involves several molecular abnormalities in 
the brain, including cerebral accumulation of extraneuronal amyloid, intraneuronal 
neurofibrillary tangles, inflammation, neurotransmitter dysfunction and eventually loss of 
neurons and synapses. Extraneuronal amyloid plaques consist of β-amyloid (Aβ) 
peptides, formed from amyloid precursor protein (APP) via endoproteolytic cleavage by 
beta-secretase1 (BACE1) and γ-secretase. These cleavages produce a variety of Aβ 
peptides, the most pathogenic being Aβ40 and Aβ42, which differ at their C-termini by 
two residues (Glenner 1984). These Aβ peptides are toxic to neurons and contribute to 
their death and dysfunction (Lambert 1998, Benilova 2012), as Aβ oligomers have been 
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shown to contribute to local synaptotoxicity by altering dendritic spine morphology 
(Kuchibhotla 2008, Wu 2010). 
In this and previous studies, we examine the effects of perinatal choline 
supplementation on AD pathology in APPswe/PS1deltaE9 (APP.PS1) mice, one of the 
most widely used AD model (Li 2015). These double transgenic mice express murine 
APP with the human Aβ amino acid sequence containing mutations responsible for a 
familial form of AD, the Swedish mutation APP (K595N/M596L; APPswe), along with a 
mutated form of a subunit of γ-secretase, presenilin 1 (PS1 exon 9 deleted; PS1dE9) 
(Campion 1995, Jankowsky 2001). APP.PS1 mice display high production of Aβ 
peptides and deposition of plaques in the brain by 6 months of age (Holcomb 1998, 
Lazarov 2002, Jankowsky 2004, Végh 2014), cholinergic defects (Payette 2007, Perez 
2007, Goto 2008, Machová 2010, Nikolajsen 2011, Burke 2013), and learning and 
memory dysfunction by 6 – 8 months of age (Savonenko 2005, Park 2006, O’Leary 2009, 
Gimbel 2010, Kemppainen 2012, Montarolo 2013).  Although transgenic mice cannot 
fully recapitulate human AD, (Gӧtz 2008) the characteristics of the APP.PS1 model are 
highly valuable for the study of this disease. Administration of perinatal choline to 
APP.PS1 mice contributes to reduced pathologies associated with AD as compared to 
control diet counterparts (Mellott 2017, Velazquez 2019). Choline supplemented mice 
display reduced soluble Aβ40 and 42 levels in the hippocampus, reduced size and 
quantity of amyloid plaques, increased β-C-terminal fragments, a metabolite of APP, a 
lack of cholinergic neuron dysfunction, and reduced levels of astrogliosis. This suggests 
that prenatal supplementation of choline could constitute a preventative strategy for AD. 
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Although prenatal choline has proven to be beneficial in adult brain function and 
ameliorative of pathogenic features of AD, the mechanisms by which it affects the brain 
still remain unclear. Basal forebrain cholinergic neurons (BFCN) synthesize and release 
the neurotransmitter acetylcholine (ACh), providing cholinergic innervation to the cortex 
and hippocampus. Availability of choline during development is critical for the 
hippocampal cholinergic system and cholinergic neurotransmission (Cermak 1998), 
which is crucial for normal learning, memory and attention throughout life (Auld 2002, 
Hasslemo 2011). During the progression of AD, basal forebrain cholinergic neurons are 
particularly vulnerable to dysfunction and degeneration (Fibiger 1991, Pedersen 1996, 
Blusztajn 2000, Auld 2002, Mufson 2003), and this loss of BFCNs contributes to the 
characteristic memory deficits of AD (Grothe 2012, Haense 2012). Brains of AD patients 
show marked degeneration of BFCNs (Grothe 2012), as do AD mouse models (Perez 
2007, Goto 2008, Machová 2010, Nikolajsen 2011). Administration of perinatal choline 
to the APP.PS1 mouse model was shown to prevent the decrease in the expression of the 
cholinergic marker, choline acetyltransferase (ChAT) (Mellott 2017), suggesting that 
choline may rescue function of BFCNs in AD. 
Acquisition of the cholinergic phenotype in basal forebrain cholinergic neurons is 
induced by bone morphogenic protein 9 (BMP9), also known as growth/differentiation 
factor 2 (GDF2) (López-Coviella 2000, 2005). BMP9 is one of more than twenty known 
BMPs, a subfamily of growth factors involved in brain development and maintenance 
(Mehler 1997). BMP9 is known to increase ACh production when administered to 
cerebral ventricles of developing mouse embryos (López-Coviella 2000), and to increase 
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expression of BFCN markers, including ChAT (López-Coviella 2000, 2005). Because of 
its importance to normal BFCN function, BMP9 administration may represent a treatment 
strategy for Alzheimer’s pathology. BMP9 infused to APP.PS1 mice 
intracerebroventricularly reduced the number of Aβ42 plaques in the hippocampus and 
cerebral cortex of 5- and 10-month old mice and prevented the reduction in ChAT protein 
levels in the hippocampus (Burke 2013). BMP9 seems to protect BFCNs from the 
pathogenic effects of AD by preserving their function. Generation of mice with Bmp9 
gene inactivations may provide insight into the mechanisms by which BMP9 affects AD 
pathology. 
Perinatal choline supplementation and BMP9 administration both support and 
preserve BFCN function and provide cognitive-enhancing and antiamyloidogenic effects 
in the APP.PS1 mouse model. This suggests that choline may act by inducing BMP9. 
This study investigates the AD-ameliorating effects of high choline during development 
as well as the effects of Bmp9 gene inactivations in the APP.PS1 mouse model of AD.  
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METHODS 
 
Animal Subjects 
All animal procedures were performed in accordance with the Animal Welfare 
Act (Animal Welfare Assurance Number A-3316-01) and the principles of the NIH 
Guide for the Care and Use of Laboratory Animals and were approved by the 
Institutional Animal Care and Use Committee of Boston University (Protocol #AN-
14994). APP.PS1 mice [strain B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax, Stock 
#034829] (Jankowsky 2001) and CHGFP mice [strain B6.Cg-Tg(RP23-268L19-
EGFP)2Mik/J] were purchased from Jackson Laboratories. Homozygous CHGFP 
females that were Bmp9+/- heterozygous were crossed with hemizygous APP.PS1 males 
that were Bmp9+/- heterozygous to generate WT and APP.PS1 mice that overexpress 
GFP in cholinergic neurons, with two (Bmp9+/+) or no (Bmp9-/-) genes to be used as 
experimental subjects. Offspring heterozygous for Bmp9 were not used in this study. 
Unless noted, animals were maintained on a standard rodent AIN76A diet (Bieri, 
1977, 1980) (Dyets #110098) consisting of 20.3% protein, 66% carbohydrate, and 5% 
fat. Specifically, this diet contained (per kg) Casein (200g), DL-methionine (3g), corn 
starch (150g), sucrose (500g), cellulose (50g), Corn oil (50g), mineral mix S10001 (35g), 
and vitamin mix V10001 (10g). Dams were given either a control AIN76A diet (Dyets 
#110098) containing 1100 mg/kg of choline chloride or a choline-supplemented diet 
(Dyets #110184) containing 5000 mg/kg of choline chloride from the time of mating until 
the offspring were weaned. After weaning at postnatal day 21, all offspring were fed a 
control diet. Mice were housed four per cage in shoebox cages with food and water ad 
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libitum. Housing and testing rooms were kept under a 12/12-hour light cycle with lights 
on at 7:00 and behavioral procedures predominantly took place between the hours of 
14:00 and 20:00.  
 
Sex Diet 
WT APP.PS1 
BMP9+/+ BMP9-/- BMP9+/+ BMP9-/- 
Female 
Control 10 4 3 4 
Supplemented 13 5 8 1 
Male 
Control 7 6 11 2 
Supplemented 4 1 9 4 
Table 1.  Number of subjects per treatment group and sex 
 
Behavior 
All mice were subjected to the same schedule of behavioral tests at 6 and 9 
months of age. Mice were weighed before the start of testing and end of testing at each 
time point and health status was monitored throughout the study. Animals were allowed 
to acclimate to the testing room for 30 minutes prior to all trials. Mice were placed in 
individual holding cages during experiments to control for potential artifacts. All testing 
arenas and implements were cleaned with 70% ethanol and allowed to dry in between 
subjects. 
 
Open Field Test 
The open field test was used to assess general exploratory locomotion using 
previously described methods (Hughes 1969, Holmes 2002, Bailey 2009, Seibenhener 
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2015). The field consists of a rectangular gridded floor (45 x 60 cm) and clear walls (45 
cm) high enough to prevent subjects from escaping. Trials occurred under low 
illumination. The trial began when the mouse was placed in the center of the field where 
it was allowed to freely explore for 30 minutes. During the 30-minute trial, total time 
spent in the central (25 x 40 cm) and peripheral (10cm around perimeter) zones of the 
arena were recorded, as well as average velocity and total distance traveled. These data 
were scored using Ethovision 9.0 software (Noldus Information Technology).  
 
Elevated Plus Maze 
 Anxiety-like behaviors were evaluated using the elevated plus maze, as described 
previously (Pellow 1985, Hogg 1996, Bailey 2009). The apparatus consists of two open, 
exposed arms (30 x 10 cm), and two closed, walled arms (30 x 10 x 46 cm) that extend 
from a central area (10 x 10 cm), with the entire maze elevated 40 cm from the floor. The 
trial began when the subject was placed in the center, facing an open arm, where it was 
then allowed to freely explore for 5 minutes. Total time spent in the open and closed arms 
as well as the center space were recorded, along with total entries into the open and 
closed arms. Entries were scored as the number of times all four of the animal’s paws 
entered into a given region. Data were scored by two viewers blind to sex and treatment 
groups and using Ethovision 9.0 software (Noldus Information Technology). 
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Barnes Maze 
 To evaluate visuo-spatial learning and memory, mice were trained on the Barnes 
maze, (Barnes 1979, Bach 1995) in which mice learn to locate an escape hole on a 
circular platform (92 cm diameter) elevated 107 cm above the floor. The maze has 20 
holes (5 cm diameter) equally spaced 2 cm from the perimeter. A dark escape pod (10 x 
10 x 8 cm) is attached under one of these holes. The maze was brightly lit and loud white 
noise was played in the testing room. Extra-maze visual cues were visible to mice on the 
walls of the testing room. The same escape pod location was used for all mice at the 6-
month time point. At 9 months, the position of the escape pod was moved 270o from the 
original position, while the extra-maze visual cues remained the same, requiring the mice 
to learn and remember new spatial information. For all Barnes maze trials, the mouse was 
placed in the center of the maze in an opaque cylinder and the trial began when the 
cylinder was removed. Mice were habituated to the maze for 2 trials occurring 18 – 22 
minutes apart. In these trials, the mouse was allowed to explore the maze for up to 2 
minutes and then guided to the escape pod. Twenty-four hours following habituation, 
mice received 3 training trials per day for 3 days (90 s trial maximum, 18 – 22 m inter-
trial interval). Mice were guided to the escape pod after 90 seconds if they failed to locate 
it during the trial. Twenty-four hours following training, mice completed a single 30-
second test (1-day probe) and another 30-second probe test 7 days later (7-day probe). 
During probe trials, the escape hole was covered and mice were prevented from escaping. 
Latency to locate the escape hole was recorded in all trials, as well as total time to escape 
during training trials, and total time spent in each quadrant in probe trials when escape 
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was prevented. The number of errors made by the mouse was counted; errors were scored 
as any time the subject’s nose crossed the perimeter of any hole other than the escape 
hole. Data were scored by viewers blind to sex treatment groups and using Ethovision 9.0 
software (Noldus Information Technology). 
 
Brain Analysis 
Immunohistochemistry 
 Upon euthanasia by CO2 inhalation at 9 months of age, brains were rapidly 
dissected and right hemispheres were immediately fixed in PLP fixative [4% (vol/vol) 
paraformaldehyde, 75mM lysine, 10 mM sodium periodate; pH 7.4] at 4 °C overnight 
and cryoprotected using 10% (vol/vol) and 20% (vol/vol) glycerol/2% (vol/vol) dimethyl 
sulfoxide in 0.1 M PBS, pH 7.3 (24 h each). Serial frozen sections (40 μm, coronal) were 
cut with a sliding microtome from the anterior frontal pole of the caudal occipital region. 
All sections intended to be subjects of comparative analyses were processed together and 
incubated for the same time periods in all of the reagents. For Aβ42 
immunohistochemistry, sections were treated with >95% (wt/vol) formic acid (Sigma) for 
2 min with gentle agitation, washed with PBS, and then transferred to a solution of 
PBS/10% (wt/vol) goat serum (Gibco) for 1 h at room temperature. Sections were probed 
with rabbit anti-Aβ42 (1:2,500; Invitrogen, #700254) overnight at RT in 0.3% Triton-X 
100, 2% (wt/vol) goat serum, and 0.008% sodium azide PBS. Following washing, 
sections were probed with goat anti-rabbit HRP (1:1,000; Millipore, #170-6515) in a 
solution of 2% (wt/vol) goat serum PBS for 3 h at RT. After incubation in a developing 
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solution containing diaminobenzidine, sodium imidazole, and hydrogen peroxide, 
sections were mounted on subbed slides. Photomicrographs were taken at 2× 
magnification objective, and images of the hippocampus, somatosensory cortex 
(anterior), and entorhinal cortex (posterior) were analyzed with ImageJ software (NIH) to 
determine the number of Aβ42-positive plaques. Entire hippocampal sections were 
included in plaque analysis. Cortical sections within given region of interest were taken 
for analysis (324.8 ± 3.2 μm2 somatosensory, 333.6 ± 2.7 μm2 entorhinal). The data are 
expressed as plaque burden, i.e. the percentage of plaque coverage in the total region of 
interest as well as total number of plaques per given section. 
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RESULTS 
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APP.PS1; p=0.0011 
Time; p<0.0001 
Time*Diet; p=0.0016 
Time*Diet*BMP9; p=0.0074 
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Figure 1. Distance traveled in the open field at 6 months of age. Open Field (OF) behavioral test was 
performed at 6 months of age for each subject. A representative trace from one subject of each group is 
shown in (A). The yellow area represents the center of the field and the red represents the periphery. 
Distance traveled during 5 minute intervals was recorded (B). (C – E) show the same data represented in 
(B) for select groups. Significant effects of genotype, diet, and time on distance traveled are indicated, as 
determined by MANOVA. 
  
Time; p<0.0001 
Time*Diet; p=0.0277 
APP.PS1; p=0.0157 
Time; p<0.0001 
Time*BMP9; p=0.0405 
APP.PS1; p=0.0249 
Time; p<0.0001 
Time*BMP9; p=0.0278 
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A 
 
  
APP.PS1; p=0.0012 
Time; p<0.0001 
Time*Diet; p=0.0016 
Time*Diet*BMP9; p=0.0050 
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C       D
 
Figure 2. Velocity in the open field at 6 months of age. Open Field (OF) behavioral test was performed at 
6 months of age for each subject. Velocities were recorded throughout the 30-minute trial and presented in 
5 minute intervals (A). (B – D) show the same data represented in (A) for select groups. Significant effects 
of genotype, diet, and time on velocity are indicated, as determined by MANOVA. 
  
APP.PS1; p=0.0187 
Time; p<0.0001 
Time*BMP9; p=0.0324 
 
APP.PS1; p=0.0248 
Time; p<0.0001 
Time*BMP9; p=0.0246 
 
Time; p<0.0001 
Time*BMP9; p=0.0228 
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A 
 
  
Time; p<0.0001 
 17 
B 
 
 
C       D 
 
Figure 3. Time spent in center region of the open field at 6 months of age. Open Field (OF) behavioral 
test was performed at 6 months of age for each subject. Data were obtained using Ethovision 9.0 software. 
Total time spent in the center region of the arena was recorded throughout the 30-minute trial and presented 
in 5 minute intervals (A). (B – D) show the same data represented in (A) for select groups. Significant 
effects of genotype, diet, and time on time in center region are indicated, as determined by MANOVA. 
Time; p<0.0001 
BMP9; p=0.0216 
Time; p=0.0011 
APP.PS1; p=0.0427 
Time; p=0.0003 
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APP.PS1; p=0.0215 
Time; p<0.0001 
Time*BMP9; p=0.0409 
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D       E 
 
 
 
Figure 4. Distance traveled in the open field at 9 months of age. Open Field (OF) behavioral test was 
performed at 9 months of age for each subject. A representative trace from one subject of each group 
throughout the trial is shown in (A). The yellow area represents the center of the field and the red 
represents the periphery. Distance traveled during each 5-minute interval was recorded throughout the 30-
minute trial (B). (C – E) show the same data represented in (B) for select groups. Significant effects of 
genotype, diet, and time on distance traveled are indicated, as determined by MANOVA. 
  
Time; p<0.0001 
Time; p<0.0001 
Time*APP.PS1; p=0.0345 
Time*BMP9; p=0.0466 
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A 
 
  
APP.PS1; p=0.0224 
Time; p<0.0001 
Time*BMP9; p=0.0346 
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C       D 
  
 
Figure 5. Velocity in the open field at 9 months of age. Open Field (OF) behavioral test was performed at 
9 months of age for each subject. Velocities were recorded throughout the 30-minute trial and presented in 
5 minute intervals (A). (B – D) show the same data represented in (A) for select groups. Significant effects 
of genotype, diet, and time on velocity are indicated, as determined by MANOVA. 
  
Time; p<0.0001 
Time; p<0.0001 
Time*APP.PS1; p=0.0342 
Time*BMP9; p=0.0400 
 22 
A 
 
  
Diet; p=0.0092 
Time; p<0.0001 
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Figure 6. Time spent in center region of the open field at 9 months of age. Open Field (OF) behavioral 
test was performed at 9 months of age for each subject. Time spent in the center area of the arena was 
recorded throughout the 30-minute trial (A). (B – D) show the same data represented in (A) for select 
groups. Significant effects of genotype, diet, and time on time in center region are indicated, as determined 
by MANOVA. 
  
Time; p<0.0001 
BMP9; p=0.0266 
Time; p=0.0002 
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We tested the effects of perinatal choline availability and Bmp9 genotype in WT 
and APP.PS1 AD-model mice on behavior using the open field (OF), elevated plus maze 
and Barnes maze tests in a longitudinal fashion when the mice were 6- and subsequently 
9-months old.  The open field test was employed to assess general exploratory 
locomotion and anxiety-like behaviors (Hughes 1969, Holmes 2002, Bailey 2009, 
Seibenhener 2015). In this test, mice are placed in the center of an open rectangular field 
and allowed to freely explore the arena for 30 minutes. During the trial, distance traveled 
(Figs. 1 and 4), velocity (Figs. 2 and 5), and time spent in the central and peripheral zones 
of the arena (Figs. 3 and 6) were recorded at 5-minute intervals. At 6 months of age, there 
was a significant effect of APP.PS1 transgenes on distance traveled (Fig. 1 B) and 
velocity (Fig. 2 A). Mice in both dietary groups with APP.PS1 transgenes traveled greater 
distances throughout the trial (Fig. 1 D and E) and at greater velocities (Fig. 2 D and E) 
than their WT counterparts, regardless of Bmp9 genes. This indicates that by 6-months of 
age, APP.PS1 mice exhibit increased locomotor activity, consistent with previous 
findings of hyperactivity in the APP.PS1 mouse model (Arendash 2001, Webster 2014).  
In the open field test, avoidance of the center area and greater time spent along the 
periphery of the field is considered an index of increased anxiety due to rodents’ natural 
avoidance of exposed, open areas (Seibenhener 2015). At 6 months of age, mice in the 
control diet group with Bmp9 gene inactivations spent more time in the center of the 
arena than Bmp9+/+ mice, regardless of APP.PS1 (Fig. 3 C). Within the choline 
supplemented group, APP.PS1 mice spent more time in the center than WT, regardless of 
Bmp9 gene status (Fig. 3 D). At this time point, it seems that APP.PS1 mice exhibit less 
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anxiety-like behavior when given supplemental choline during development. The low 
anxiety levels of Bmp9-/- non-AD model mice were not apparent when given 
supplemental choline. 
There was an overall effect of APP.PS1 transgenes on distance traveled and 
velocity in the OF once again at 9 months of age (Figs. 4 B and 5 A). AD mice traveled 
farther and faster than WT mice, indicating greater motor activity at this time point. 
Within the control diet group, there was an interaction effect of time and BMP9 on both 
distance traveled (Fig. 4 D) and velocity (Fig 5 C). Mice with Bmp9 gene inactivations 
showed high levels of distance and velocity at the onset of the trial followed by a sharp 
decline in these parameters. Bmp9+/+ mice did not display this shift. No effects of BMP9 
or APP.PS1 on locomotor activity were evident in the choline supplemented group (Figs. 
4 E and 5 D). Within the Bmp9+/+ group, there were no significant effects of diet or 
APP.PS1 transgenes on distance traveled (Fig. 4 C) or velocity (Fig. 5 B). This may 
further indicate that inactivation of Bmp9 genes drives some hyperactivity behaviors. 
Time spent in the center of the arena was significantly affected by diet and time at 
9 months (Fig. 6 A). Perinatal choline supplemented mice spent less time in the center 
than control diet mice overall, indicating some increased anxiety levels with choline 
supplementation. Similar to 6-month data, within the control diet group, Bmp9-/- mice 
spent far more time in the center than Bmp9+/+ mice, regardless of APP.PS1 status (Fig. 
6 C), and this effect was not observed in the perinatal choline diet group (Fig. 6 D). This 
again indicates that reduced anxiety behaviors associated with Bmp9 gene deficiency are 
not apparent when mice are given supplemental choline during development.   
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Figure 7. Elevated Plus Maze performance at 6 months of age. Subjects were tested on the elevated plus 
maze (EPM) at 6 months of age. Total time spent in each arm and middle section of the maze were 
recorded (A) as well as the number of entries into each arm (B). Means ± SEM are presented per treatment 
group. A representative aerial trace from each group is shown in (C). Vertical arms are closed and 
horizontal arms are open. Total time spent in open and closed arms and entries into arms were not 
significantly affected by diet, BMP9, or APP.PS1 (p>0.05). Data were determined by three-way ANOVA. 
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Figure 8. Elevated Plus Maze performance at 9 months of age. Subjects were tested on the elevated plus 
maze (EPM) at 9 months of age. Total time spent in each arm and middle section of the maze were 
recorded (A) as well as the number of entries into each arm (B). Means ± SEM are presented per each 
treatment group. A representative aerial trace from each group is shown in (C). Vertical arms are closed 
and horizontal arms are open. Among supplemented-diet mice, a 2-way ANOVA for BMP9 and APP.PS1 
and Tukey test reveals that APP.PS1/Bmp9-/- mice spend more time in the open arms than their Bmp9+/+ 
counterparts (p=0.0095). Diet, BMP9 status and APP.PS1 genotype did not significantly affect number of 
entries (p>0.05). 
0
2
4
6
8
10
12
14
16
18
Closed Arms Open Arms
N
u
m
b
e
r 
o
f 
E
n
tr
ie
s
9M
Control WT BMP9+/+
Control APP.PS1 BMP9+/+
Supplemented WT BMP9+/+
Supplemented APP.PS1 BMP9+/+
Control WT BMP9-/-
Control APP.PS1 BMP9-/-
Supplemented WT BMP9-/-
Supplemented APP.PS1 BMP9-/-
 30 
The elevated plus maze (EPM) apparatus consists of two open, exposed arms and 
two closed, walled arms that extend from a central area, with the entire maze elevated 40 
cm from the floor. Because mice with greater anxiety tend to avoid bright and exposed 
spaces, they typically spend the majority of their time on the elevated plus maze in the 
sheltered, closed arms. During the 5-minute trial, each mouse is placed in the center of 
the apparatus and allowed to freely explore. Total time spent in open and closed arms and 
middle region were recorded as well the number of entries made into open and closed 
arms. Greater time spent in the open arms and more entries into the open arms are 
considered an indication of reduced anxiety-like behavior. Previous studies in APP.PS1 
mice find that they exhibit reduced anxiety levels as compared to WT controls (Lalonde 
2004, Reiserer 2007), although in our study APP.PS1 transgenes alone did not influence 
EPM behavior. At 6 months of age, there were no significant effects of diet, APP.PS1 
genotype, or BMP9 status on EPM parameters (Fig. 7). At 9 months, Bmp9 gene 
inactivations seem to have some effect on EPM behavior. Within the perinatal choline 
supplemented group, APP.PS1/Bmp9-/- mice spent significantly more time in the open 
arms than their Bmp9+/+ non AD-model counterparts (Fig. 8 A). This effect was not 
observed in the control diet group. These data suggest that perinatal choline 
supplementation and BMP9 deficiency leads APP.PS1 mice to exhibit less caution and 
anxiety in the EPM. 
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Figure 9. Barnes maze training latency to target hole at 6 months of age. Subjects were trained to find 
an escape pod on the Barnes maze at 6 months of age over the course of 3 trial days with 3 trials per day. A 
representative trace from a single subject is shown in (A) and a diagram of the arena is shown in (B). Total 
time required to locate the target hole was recorded per trial and averaged per day of training per animal. 
The means ± SEM per group are represented over the 3 days of training in (B). (C – E) show the same data 
represented in (B) for select groups. Significant effects of genotype, diet, and time on latency to target hole 
are indicated, as determined by MANOVA. All Bmp9+/+ groups exhibit decreased latency from training 
day 1 to 3 (p<0.05) while Bmp9-/- groups do not show significant changes in latency during training 
(p>0.05). 
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Figure 10. Barnes maze training latency to escape at 6 months of age. Total time required to escape (A 
– D) was recorded over the course of 3 trial days with 3 trials per day. Total time required to enter the 
escape pod was recorded per trial and averaged per day of training per animal. The means ± SEM per group 
are represented over the 3 days of training in (A). (B – D) show the same data represented in (A) for select 
groups. Significant effects of genotype, diet, and time on latency to escape are indicated, as determined by 
MANOVA.   
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Figure 11. Barnes maze training errors at 6 months of age. Total number of errors made (A – D) was 
recorded over the course of 3 trial days with 3 trials per day. The number of errors per mouse were 
averaged per day of training, and the means ± SEM per group are represented over the 3 days of training in 
(A). (B – D) show the same data represented in (A) for select groups. Significant effects of genotype, diet, 
and time on errors made are indicated, as determined by MANOVA. 
  
Time; p<0.0001 
Time*APP.PS1; p=0.0039 
 
Time; p<0.0001 Time; p<0.0001 
Time*APP.PS1; p=0.0145 
 
 37 
A 
 
B 
 
  
 38 
C 
  
D       E 
 
 
Figure 12. Barnes maze 6-month probe data. Mean values for each probe day are presented ± SEM. 
Time spent in each quadrant at the 1-day probe (A) and the 7-day probe (B) as well as latency to locate 
target hole (C), number of errors made (D), and mean distance to target hole (E) are shown. Three-way 
ANOVA for diet, APP.PS1 status, and Bmp9 genotype and Tukey test per probe day reveal a significant 
effect of AD genotype on latency during 1-day probe (p=0.0208) and diet on latency during the 7-day 
probe (p=0.0136). There was also a significant effect of APP.PS1 status on mean distance to target hole on 
the 7-day probe (p=0.0209). Number of errors made does not significantly differ among groups (p>0.05). 
In (A – B), * indicates that time spent in target quadrant is significantly greater (p<0.05) than time spent in 
all other quadrants.  
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Figure 13. Barnes maze training latency to target hole at 9 months of age. Subjects were trained to find 
an escape pod on the Barnes maze at 9 months of age over the course of 3 trial days with 3 trials per day. A 
representative trace from a single subject is shown in (A) and a diagram of the arena is shown in (B). Total 
time require to locate the target hole was recorded per trial and averaged per day of training per animal. 
The means ± SEM per group are represented over the 3 days of training in (B). (C – E) show the same data 
represented in (B) for select groups. Significant effects of genotype, diet, and time on latency to target hole 
over the course of 3 training days are indicated, as determined by MANOVA. When comparing mean 
latency to target on training day 1 versus day 3, only WT/Bmp9+/+ mice exhibit decreased latency times 
(p=0.00349) within the control diet groups. Of the supplemented-diet groups, all show reduced latency to 
target hole over time (p<0.05) except the APP.PS1/Bmp9-/- group (p=0.1045).  
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Figure 14. Barnes maze training latency to escape at 9 months of age. Total time to enter the escape 
pod was recorded per trial and averaged per day of training per animal. The means ± SEM per group are 
represented over the 3 days of training in (A). (B – D) show the same data represented in (A) for select 
groups. Significant effects of genotype, diet, and time on latency to enter the escape pod are indicated, as 
determined by MANOVA. 
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Figure 15. Barnes Maze errors at 9 months of age. The number of errors per mouse was averaged per 
day of training, and the means ± SEM per group are represented over the 3 days of training in (A). (B – D) 
show the same data represented in (A) for select groups. Number of errors (A – D) was recorded over the 
course of 3 trial days with 3 trials per day. Significant effects of genotype, diet, and time on number of 
errors are indicated, as determined by MANOVA. On training day 3, control APP.PS1/Bmp9+/+ mice 
make more errors than control WT/Bmp9+/+ mice (p=0.0506, student t-test). 
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Figure 16. Barnes maze probe data at 9 months of age. Mean values per group for each probe day are 
presented ± SEM. Time spent in each quadrant at the 1-day probe (A) and the 7-day probe (B) as well as 
latency to locate target hole (C), number of errors made (D), and mean distance to target hole (E) are 
shown. There are significant effects of AD genotype (p=0.0370) and diet (p=0.01198) on latency during 1-
day probe, as determined by three-way ANOVA and Tukey test. In (A – B), * indicates that time spent in 
target quadrant is significantly greater (p<0.05) than time spent in all other quadrants. 
 
  
 47 
To evaluate spatial learning and memory, mice were trained on the Barnes maze 
(BM), a hippocampal-dependent test in which mice learn the location of an escape pod 
based on extra-maze spatial cues (Barnes 1979). In this study, latency to locate the target 
hole, latency to enter the escape pod beneath the target hole, and number of errors made 
during training are used as indices of memory performance. During probe days, latency 
to locate the target, number of errors made, mean distance from the target, and time spent 
in BM quadrants are also measured as indices of visuo-spatial memory. In previous 
studies, APP.PS1 mice have shown impaired learning by 7 months of age in BM, making 
more errors than wild-type mice (Reiserer 2007, O’Leary 2009). At the 6-month time 
point, all animals learned the task by day 3, but certain groups exhibited impairments in 
memory performance. During training, both control and supplemented-diet WT/Bmp9+/+ 
mice showed a significant reduction in latency to locate the target from day 1 to 3, 
indicating that they learn and remember the location of the target over the course of 
training, and find it more quickly by day 3 (Fig. 9 C).  Although latencies were higher 
than other groups during training, control and choline supplemented-diet 
APP.PS1/Bmp9+/+ mice exhibited reductions in latency from day 1 to 3, suggesting 
effective learning of the task, however, they do so at varying degrees. While control 
WT/Bmp9-/- mice did not appear to be impaired, APP.PS1/Bmp9-/- mice of the same 
dietary group exhibited greater latencies locating the target hole across training days 1 – 3 
(Fig. 9 D), while perinatal choline supplemented APP.PS1 mice, regardless of BMP9 
status, were not impaired in this manner (Fig. 9 E).  
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Because BM utilizes rodents’ natural avoidance of open and bright spaces and 
their aversion to loud noise as motivation to locate the escape hole, mice that have lower 
anxiety levels may not be as motivated to locate the target hole and escape. Although 
mice are trained to locate and enter the escape pod, increased latency to escape may 
indicate that a subject lacks motivation to escape, rather than impaired memory. 
Inactivation of the Bmp9 genes seemed to have a significant impact on latency to escape. 
Bmp9-/- mice of both diet groups took significantly longer to enter the escape pod than 
their Bmp9+/+ counterparts (Fig. 10 A, C, D). This may be an indication that Bmp9-/- 
mice are less motivated to escape than Bmp9+/+ mice due to lower levels of anxiety. At 6 
months of age, neither APP.PS1 status nor diet altered the latency to escape. 
In this current study, the number of errors made during the BM by mice at 6 
months of age was not affected by diet, APP.PS1 status, or the presence of BMP9 (Fig. 
11). In general, all groups of mice made a relatively low number of errors and the errors 
decreased over the trial days indicating a successful acquisition of the task by training 
day 3. 
 Following the 3 days of training, we performed two probe tests: 1 day after the 
last day of training and 7 days after training was complete. We recorded the latency to the 
plugged target hole, number of errors made before locating the target, mean distance 
from the target hole, and time spent per quadrant of the Barnes maze. During the 1-day 
probe test at 6 months, APP.PS1/Bmp9-/- mice of both diet groups did not spend 
significantly more time the target zone compared to other quadrants (Fig. 12 A), 
however, their latencies to the target hole were relatively low which suggests that they 
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find the target quickly, but leave the target quadrant to explore elsewhere. This effect was 
not observed during the 7-day probe (Fig. 12 B). There was an overall effect of AD 
genotype on latencies to the target hole during the 1-day probe such that APP.PS1 mice 
exhibited greater latencies than their same-diet WT counterparts (Fig. 12 C). During the 
7-day probe, perinatal choline supplementation led to significantly shorter latencies in 
locating the target across all genotypes (Fig. 12 C). Again, the number of errors was not 
an effective index for measuring differences between the groups at this age since all 
groups made relatively few errors during the probe tests (Fig. 12 D). 
At 9 months all animals were able to learn the location of the escape hole, but 
certain groups did not show a significant improvement in latency times from training day 
1 to 3 that would indicate better memory and learning. Similar to the 6-month test, 
control-diet AD mice required more time to locate the escape pod than WT mice during 
BM training at 9 months (Fig. 13 C). This impairment was not observed among AD mice 
given supplemental choline during development (Fig. 13 D). The APP.PS1/Bmp9-/- mice 
of both diet groups did not exhibit significantly different latencies between days 1 and 3 
(Fig. 13 B), indicating that these mice did not learn the location of the target hole as 
quickly as the other groups. In a similar pattern, control diet WT/Bmp9-/-, 
APP.PS1/Bmp9+/+, and APP.PS1/Bmp9-/-  mice consistently took longer to locate the 
target hole than control WT/Bmp9+/+ mice (Fig. 13 C), but no significant differences 
were observed between the four groups that were perinatally supplemented with choline 
(Fig. 14 D). These data indicate that perinatal choline supplementation is ameliorative of 
memory deficits in APP.PS1 mice and Bmp9-/- mice. 
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Latency to escape was again influenced by inactivation of Bmp9 genes when 
assessed at 9 months. Bmp9-/- mice in all groups took significantly more time to escape 
than Bmp9+/+ mice, and this was especially evident among control-diet WT mice (Fig. 
14 C, D). This may indicate a continued lack of motivation to escape among Bmp9-/- 
mice. Additionally, control-diet APP.PS1/Bmp9+/+ mice took significantly more time to 
escape than their WT counterparts (Fig. 14 B). 
As before, most of the groups of mice made fewer errors as the training 
progresses from day 1 to day 3, except the control APP.PS1/Bmp9+/+ mice who 
consistently made approximately 7 errors throughout training and did not improve (Fig. 
15 A, C). On training day 3, the number of errors in this group was significantly higher 
than in the control WT/Bmp9+/+ mice. Choline supplementation and BMP9 status did not 
have an effect on the number of errors (Fig 15 A). 
During the 1-day probe test, AD mice had greater latencies to the target than WT 
and perinatal choline supplemented mice had reduced latencies compared to control diet 
mice (Fig. 16 C).  During this test, control-diet APP.PS1/Bmp9-/- mice spent a significant 
amount of time outside of the target quadrant (Fig. 16 A). These mice repeated this 
behavior during the 7-day probe, along with control-diet APP.PS1/Bmp9+/+ mice (Fig. 
16 B). This may indicate memory impairment due to APP.PS1 transgenes, as evidenced 
by the increased latencies to the target hole of both groups of mice in training (Fig. 13 B). 
In the case of Bmp9-/- mice, this behavior may indicate lower levels of anxiety and 
greater exploratory behavior. 
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Figure 17. Aβ42 plaques in hippocampus and cortex. Anterior hippocampal and somatosensory cortical 
sections from representative 9-month individuals from each group (A) were stained with an anti-Aβ42 
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antibody (Invitrogen). Entire hippocampal regions were used for quantitation and representative 
somatosensory cortical sections were outlined in black (324.8 ± 3.2 μm2), as shown, and used for 
quantitation. Posterior hippocampal sections are shown in (B) and entorhinal cortical sections were outlined 
in black (333.6 ± 2.7 μm2) in (C). Images of posterior regions in (B) and (C) are rotated 90o so that the 
lateral side of the brain is at the top of the image. Plaque burden (D – G) was calculated using ImageJ 
software as percent of area in region of interest (hippocampus or outlined area of cortex) covered by Aβ42-
positive straining. Plaque Count (H – K) represents the number of Aβ42-positive plaques in a given region. 
Means ± SEM per treatment group and sex are presented for each of the brain subregions. There were 
significant differences between males and females in each subregion used for quantification (p < 0.005) as 
determined by one-way ANOVA. Two-way ANOVA for diet and BMP9 reveals a significant overall effect 
of BMP9 on male plaque burden (p=0.0345) and plaque count (p=0.0055) in anterior hippocampus. In (H 
& I), * represents a significant effect of diet (p<0.05) between indicated groups from two-way ANOVA for 
diet and BMP9. 
 
To evaluate amyloid plaque development, coronal sections from right 
hemispheres of APP.PS1 mice were obtained and stained with anti-Aβ42. 
Photomicrographs were taken at 2× magnification objective, and images of the 
hippocampus (Fig. 17 A, B), somatosensory cortex (Fig. 17 A), and entorhinal cortex 
(Fig. 17 C) were analyzed to determine the percentage of area covered by Aβ42-positive 
staining, or plaque burden (Fig. 17 D – G) and the number of Aβ42-positive plaques (Fig. 
17 H – K). Entire hippocampal sections were included in plaque analysis and cortical 
sections within indicated region of interest were taken for analysis.  
 Females exhibited greater plaque burden and plaque counts than males in all 
regions analyzed. This is consistent with previous reports that females are more 
vulnerable to amyloidosis than males in mouse models of AD (Wang 2003, Burke 2013, 
Jiao 2016). In humans, women are at a greater risk of developing AD than men 
(Andersen 1999). In this study plaque counts in female and male anterior hippocampus 
(Fig. 17 H), and female posterior hippocampus (Fig. 17 I) were significantly higher in 
animals that had received supplemental perinatal choline than control diet. This 
contradicts previous findings that APP.PS1 mice develop fewer hippocampal Aβ42 
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plaques following perinatal choline supplementation as compared to perinatal control diet 
(Mellott 2017, Velazquez 2019).  
In Bmp9-/- males, plaque burden was lower in the anterior hippocampus as 
compared to Bmp9+/+ mice regardless of diet (Fig. 17 D). No significant effects of 
BMP9 or diet were observed in the somatosensory or entorhinal cortex regions analyzed. 
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DISCUSSION 
 These data show that high dietary choline availability throughout development 
and the presence of BMP9 impact the pathologic behavioral features of the AD mouse 
model. Both cognitive and noncognitive behaviors are symptomatic of AD, with an 
estimated 90% of patients experiencing some noncognitive symptoms (Savva 2009, 
Masters 2015). The APP.PS1 mouse model of AD used in this study has been shown to 
exhibit increased locomotor activity (Arendash 2001, Cheng 2014, Webster 2014) and 
reduced anxiety levels (Lalonde 2004, Reiserer 2007). In this study, APP.PS1 mice 
exhibited heightened locomotor activity at both the 6 and 9-month time points in the OF 
test. APP.PS1 mice of both dietary groups traveled greater distances and with greater 
velocity throughout the trial than WT mice, regardless of the presence or absence of 
BMP9, indicating increased motor activity. At the 9-month time point, mice with Bmp9 
gene deficiency also displayed somewhat increased locomotor activity in the OF test, 
primarily in APP.PS1 mice. APP.PS1/Bmp9-/- mice within the control diet group 
exhibited the highest distances traveled and velocities at multiple time points during the 
trial. This pattern of hyperactivity was not apparent within the choline supplemented 
group, suggesting that additional dietary choline during development may reduce 
hyperactivity associated with APP.PS1 or BMP9 status. 
In the OF test, greater time spent in the periphery and avoidance of the center 
region may be considered an index of more cautious and anxious behavior (Seibenhener 
2015). Although the APP.PS1 model has been shown to display reduced anxiety in other 
studies (Lalonde 2004, Reiserer 2007), APP.PS1 transgenes only contributed to time 
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spent in the center region of the OF at 6 months of age. Choline supplemented APP.PS1 
mice spent more time in the center of the field than their WT counterparts, regardless of 
BMP9. Because this effect was not observed in the control-diet group, this may indicate 
that perinatal choline supplementation of APP.PS1 mice further reduces anxiety-like 
behavior at 6 months. At both 6 and 9 months of age, control-diet Bmp9-/- mice spent 
more time in the center of the OF than their Bmp9+/+ counterparts, regardless of 
APP.PS1 transgenes. This behavior did not occur in the choline supplemented group. 
This may indicate that reduced anxiety behaviors associated with Bmp9 gene deficiency 
are not apparent when mice are given supplemental choline during development. 
In the EPM test of anxiety-like behavior, greater time spent in the open arms of 
the maze is associated with reduced anxiety because mice are naturally averse to bright 
and open spaces. Although APP.PS1 mice have previously shown lower levels of anxiety 
(Lalonde 2004, Reiserer 2007), in this study APP.PS1 transgenes alone did not seem to 
influence behavior in the EPM. Bmp9 gene status, however, did seem to influence 
anxiety-like behavior in the EPM at 9 months of age. Within the choline-supplemented 
group, APP.PS1/Bmp9-/- mice spent more time in the open arms than their Bmp9+/+ 
counterparts. This effect was not evident in the control diet group. These data suggest that 
perinatal choline supplementation and Bmp9 gene deficiency lead APP.PS1 mice to 
exhibit lower levels of anxiety in the EPM. Interestingly, these data partially contradict 
findings from the OF. In the OF, Bmp9-/- mice exhibited lower levels of anxiety than 
Bmp9+/+ mice by spending more time in the center of the maze when they received 
control diet, and choline supplementation of Bmp9-/- mice led to exhibit anxiety behavior 
 62 
similar to Bmp9+/+ mice. In the OF a general effect of Bmp9 gene inactivation on anxiety 
in control mice was observed regardless of APP.PS1 genes. In the EPM, Bmp9 gene 
deficiency and diet seemingly only affected APP.PS1 mice and this may account for the 
discrepancy. 
 Previous studies have shown that APP.PS1 mice exhibit learning and memory 
dysfunction by 6 – 8 months of age (Savonenko 2005, Park 2006, O’Leary 2009, Gimbel 
2010, Kemppainen 2012, Montarolo 2013). The Barnes maze test of visuo-spatial 
memory was used in this study to evaluate their cognitive deficits. In this test, latency to 
locate the target hole, latency to enter the escape pod beneath the target hole, and number 
of errors made during training are used as indices of learning and memory performance. 
During probe days, latency to locate the target, number of errors made, mean distance 
from the target, and time spent in BM quadrants are also measured as indices of visuo-
spatial memory. Previous studies report that APP.PS1 mice are impaired in BM (Reiserer 
2007, O’Leary 2009), which is consistent with our results. During 6-month training, all 
mice effectively learned the task, although learning occurred at varying degrees among 
groups. In the control diet group, WT/Bmp9-/- were not impaired, while APP.PS1/Bmp9-
/- mice exhibited memory impairments. Perinatal choline supplemented APP.PS1 mice, 
however, did not exhibit poorer memory performance, regardless of Bmp9-/- status. This 
suggests that perinatal choline allows APP.PS1/Bmp9-/- mice to learn at a similar rate as 
WT mice in BM training. During the 7-day probe test at this age, perinatal choline 
supplement was shown to reduce latencies locating the target across all genotypes. This is 
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consistent with other findings that visuo-spatial learning deficits in APP.PS1 mice are 
improved by supplemental perinatal choline (Velazquez 2019). 
 Consistent with 6-month results, at 9 months, control diet APP.PS1 mice required 
more time to locate the escape pod than WT during BM training, and this impairment was 
not observed among AD mice given supplemental choline during development. 
Additionally, control diet WT/Bmp9-/-, APP.PS1/Bmp9+/+, and APP.PS1/Bmp9-/- did 
not significantly improve their latencies to the target pod over 3 days of training, 
indicating that they did not effectively learn and remember the location of the target. 
Choline supplemented counterparts significantly reduced their latencies over the course 
of training and exhibited successful learning of the task. APP.PS1/Bmp9-/- mice did not 
exhibit effective learning regardless of diet. These data further indicate that perinatal 
choline supplementation is ameliorative of memory deficits in APP.PS1 mice and Bmp9-
/- mice. During the 1-day probe trial, perinatal choline supplementation overall reduced 
latencies to the target pod as compared to control diet. 
An important aspect of the BM to consider is that it utilizes anxiety as motivation 
to locate the escape pod. This presents a potential drawback when evaluating mice with 
differing anxiety levels. Bright light and loud white noise are employed to help induce 
mild stress, but this may not be enough motivation for certain mice to immediately 
escape. Although mice are trained to locate and enter the escape pod, increased latency to 
escape may indicate that a subject lacks motivation to escape, rather than impaired 
memory. In this study, inactivation of Bmp9 genes seemed to have a significant impact on 
latency to escape. Bmp9-/- mice had reduced anxiety levels in the OF and EPM, and this 
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may account for their apparent mild impairment in BM. At 6 months, Bmp9-/- mice of 
both diet groups took significantly longer to enter the escape pod than their Bmp9+/+ 
counterparts, which may be an indication that Bmp9-/- mice are less motivated to escape 
than Bmp9+/+ mice due to lower levels of anxiety. During the 1-day probe test, 
APP.PS1/Bmp9-/- mice of both diet groups did not spend significantly more time in the 
target zone compared to other quadrants, however, their latencies to the target hole were 
relatively low. This suggests that they find the target quickly, but leave the target 
quadrant to search elsewhere because they exhibit greater exploratory behavior. Latency 
to escape was not significantly influenced by diet at 6 months. 
At 9 months, Bmp9 gene status again influenced latency to escape. Bmp9-/- mice 
in all groups took significantly more time to escape than Bmp9+/+ mice, and this is 
especially evident among control-diet WT mice. This may indicate a continued lack of 
motivation to escape among Bmp9-/- mice. Additionally, control-diet APP.PS1/Bmp9+/+ 
mice took significantly more time to escape than their WT counterparts at the 9-month 
time point, which could also indicate a lack of motivation to enter the escape pod. 
Coupled with the lower levels of anxiety observed among AD mice in OF, these mice 
may exhibit impaired BM performance partly due to a lack of motivation to escape. 
However, because APP.PS1 mice are also impaired in other tests of visuo-spatial memory 
like the Morris water maze (O’Leary 2009, Velazquez 2019), they are likely impaired in 
the BM due to cognitive deficits induced by their APP.PS1 transgenes rather than 
reduced anxiety levels. Diet did not significantly influence escape latency at this age.  
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 Previous reports show that poorer performance in tests of memory and cognition 
are closely associated with increased amyloid plaques in AD mouse models (Reiserer 
2007, O’Leary 2009, Velazquez 2019). In this study, the data obtained from BM trials 
indicate that perinatal choline supplemented APP.PS1 mice are less impaired in visuo-
spatial memory and cognition than control diet mice. This would suggest that 
supplemented mice have fewer Aβ plaques affecting their cognition. Additionally, 
perinatal choline supplementation has been shown to be ameliorative of AD pathology, 
including Aβ42 plaque levels in the hippocampus of the APP.PS1 model (Mellott 2017, 
Velazquez 2019). However, this was not the case in our study. In contrast with behavioral 
data and the findings of previous studies, perinatal choline supplemented mice developed 
significantly more amyloid plaques than control diet mice in certain hippocampal areas. 
The Aβ42 staining performed in this study indicates that perinatal choline 
supplementation increases plaque number in female and male anterior hippocampi and 
female posterior hippocampi. Perinatal diet did not affect amyloid plaque development in 
cortical sections used in this study. In humans, the somatosensory cortex has been shown 
to exhibit functional impairments early in the progression of the disease that likely impact 
behavior (Stephen 2010). This area is also shown to be affected by Aβ in a mouse model 
of AD early on in the disease progression (Suvà 1999), although hippocampi were 
affected earlier than somatosensory cortical areas. Entorhinal cortex has been shown to 
be one of the first areas of the brain to accumulate amyloid plaques, along with the 
dentate gyrus of the hippocampus in a mouse model of AD (Reilly 2003). In this study, 9-
month old mice expressed significantly different levels of amyloid plaques between 
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groups in hippocampi, but did not express differing Aβ42 plaque levels in cortical 
regions. This may be a consequence of small cortical sample areas, or it may indicate that 
perinatal choline does not affect amyloid plaque development in the cortices. APP.PS1 
mice that exhibit fewer memory impairments in the BM with perinatal choline 
supplementation, but increased hippocampal plaques may rely on entorhinal cortex 
function where there are no differential amyloid plaque levels. 
Another interesting finding is that inactivation of Bmp9 genes seemingly 
contribute to reduced amyloid plaque development. Male Bmp9-/- groups had lower 
Aβ42 plaque burden and plaque count in anterior hippocampus than Bmp9+/+ groups. 
Because the exogenous administration of BMP9 resulted in fewer Aβ42 plaques in the 
hippocampus and cerebral cortex of APP.PS1 mice (Burke 2013, Wang 2017), one might 
expect Bmp9 gene inactivation to have the opposite effect, leading to greater amyloid 
plaque development. It was suggested that the infusion of exogenous BMP9 may provide 
support for cholinergic neurons and their innervation of the hippocampus in order to 
promote plaque clearance and inhibit new plaque formation, but the inverse may not 
necessarily be true for Bmp9-/- individuals. Other BMPs have also been shown to 
upregulate the cholinergic phenotype, although less efficiently than BMP9 (López-
Coviella 2000). Absence of BMP9 may lead to upregulation of alternative BMPs which 
may induce alternate effects on BFCN function and plaque development. The effects of 
Bmp9 gene inactivation on behavior and AD pathology are largely unknown. The data 
from this study suggest that Bmp9 gene deficiency reduces anxiety-like behavior and 
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amyloid plaque development, but the mechanisms by which this occurs require further 
investigation. 
 Despite contradictory amyloid plaque data, perinatal choline supplementation 
ameliorates the behavioral impairments observed in the APP.PS1 mouse model of AD. 
These findings support previous literature indicating the life-long beneficial effects of 
supplemental choline during development on cognitive function. In the context of AD, 
dietary factors that affect cognitive function could represent a valuable preventative 
strategy. Inactivation of Bmp9 genes seems to contribute to lower levels of anxiety, and 
amyloid plaque levels, however further study of its effects on AD pathology and perinatal 
choline supplementation may be required.   
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